Skip to main content
SpringerLink
Log in
Book cover

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

  • Book
  • © 2018

Overview

Editors:
  1. Yosef Yarden

    1. Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Moshe Elkabets

    1. Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheeva, Israel

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer
  • Examines specific targets and the cognate drugs
  • Evaluates molecular modes of innate and evolving resistance

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 15)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages i-xx
    Download chapter PDF

  2. Resistance of Colorectal Tumors to Anti-EGFR Antibodies

    • Livio Trusolino, Simonetta M. Leto
    Pages 1-27

  3. Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK

    • Maicol Mancini, Yosef Yarden
    Pages 29-49

  4. Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer

    • Jennifer L. Hsu, Mien-Chie Hung
    Pages 51-66

  5. Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis

    • Simona Corso, Silvia Giordano
    Pages 67-87

  6. RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge

    • Galia Maik-Rachline, Izel Cohen, Rony Seger
    Pages 89-116

  7. Mechanisms of Resistance to PI3K and AKT Inhibitors

    • Pau Castel, Maurizio Scaltriti
    Pages 117-146

  8. Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy

    • Konstantinos V. Floros, Anthony C. Faber, Hisashi Harada
    Pages 147-180

  9. Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors

    • Wolf Ruprecht Wiedemeyer
    Pages 181-210

  10. Resistance to Inhibitors of Angiogenesis

    • Nili Dahan, Ksenia Magidey, Yuval Shaked
    Pages 211-236

  11. Back Matter

    Pages 237-242
    Download chapter PDF
Back to top

Keywords

About this book

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Editors and Affiliations

  • Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

    Yosef Yarden

  • Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheeva, Israel

    Moshe Elkabets

About the editors

Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Bibliographic Information

  • Book Title: Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

  • Editors: Yosef Yarden, Moshe Elkabets

  • Series Title: Resistance to Targeted Anti-Cancer Therapeutics

  • DOI: https://doi.org/10.1007/978-3-319-67932-7

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing AG, part of Springer Nature 2018

  • Hardcover ISBN: 978-3-319-67930-3Published: 10 April 2018

  • Softcover ISBN: 978-3-030-09817-9Published: 02 February 2019

  • eBook ISBN: 978-3-319-67932-7Published: 28 March 2018

  • Series ISSN: 2196-5501

  • Series E-ISSN: 2196-551X

  • Edition Number: 1

  • Number of Pages: XX, 242

  • Number of Illustrations: 22 illustrations in colour

  • Topics: Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation